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Introduction
Whether we think of Alzheimer’s dis-
ease, microbial infection, or any other
modern-day disease, new medicines are
urgently needed. The number of new
drugs registered since the advent of
genomics, however, has not lived up to
expectations. One recent review revealed
that over 70 high-throughput biochemical
screens against genetically validated drug
targets in bacteria failed to yield a single
candidate that could be tested in the clinic
[1]. The reasons for the failure of high-
throughput biochemical screens are not
completely clear, but it could reflect the
limited diversity of chemical libraries used
and/or the absence of structural informa-
tion for many of the targets. Indeed,
structure-based drug design is playing a
growing role in modern drug discovery,
with numerous approved drugs tracing
their origins, at least in part, to the use of
structural information from X-ray crystal-
lography or nuclear magnetic resonance
(NMR) analysis of protein targets and their
ligand-bound complexes. Although it is
beyond the scope of this brief overview to
present a comprehensive list of structures
that have led to useful drugs, Table 1 lists
some examples in which protein structure
information has provided insights to the
design and development of new therapeu-
tic entities. These cases include both novel
drug design based on native and ligand-
bound structures and optimization of
inhibitors based on the binding mode
revealed by the structures of inhibitor–
target complexes. These approaches have
allowed increased affinity for the target
and/or improvement of pharmacological
properties while maintaining target
affinity.
With the increasing availability of
complete human and pathogen genome
sequences and the substantial progress in
structure determination methods, it is no
surprise that the field of ‘‘structural
genomics’’ has emerged recently. Its aim
is to solve as many useful protein struc-
tures as possible from the entire genome of
a single organism or group of related
organisms. Over the past ten years, over
20 structural genomics initiatives have
begun around the world (Table 2). The
impact of these efforts on structural
biology has been substantial, both in the
sheer number of new structures and,
perhaps even more importantly, in the
development of new methodologies, espe-
cially the use of robotics and informatics to
generate and capture data in a systematic
way [2]. Over the next five years,
thousands of new protein structures, many
bound to their ligands, will be elucidated;
laying the groundwork for structure-
based design and development of new
and improved chemotherapeutic agents
against pathogen proteins. Here, we will
focus on the intersection of structural
biology with chemistry and biology—a
field called ‘‘medical structural geno-
mics’’—particularly on how the structures
of medically relevant drug targets in
pathogens can serve as a starting point
for inhibitor design and drug develop-
ment. We argue that the pharmaceutical
industry should be persuaded to comple-
ment the publicly funded structural geno-
mics initiatives by making public the
structural coordinates of their drug targets
for important infectious disease organisms
in a timely fashion and by developing
public–private partnerships to provide the
maximal synergy between target valida-
tion, structure determination, and hit-to-
lead development.
Target Selection
A prerequisite of medical structural
genomics is that the proteins whose
structures are determined must be well-
validated as good drug targets. The term
‘‘drugability’’ is often used to loosely
describe how tractable any given target is
for the development of a drug candidate.
For infectious organisms, one key factor in
defining drugability is that the target
protein be essential for survival of the
microbe. While essentiality has tradition-
ally been defined using techniques such as
‘‘gene knockout’’ and RNA interference,
these are not always feasible and should be
complemented by chemical biology ap-
proaches (see below). Furthermore, the
meaningfulness of these experiments can
often be difficult to assess, since the
interplay of host and pathogen is complex
and full of surprises. For example, tre-
mendous effort has been devoted recently
to the development of antagonists for
targets in the fatty acid biosynthesis
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molecules with high bioavailability have
been developed that can effectively shut
down bacterial replication in vitro. These
compounds were found to be ineffective in
subsequent animal testing, however, be-
cause fatty acids are quite abundant in
vertebrates, so bacteria can secure these
host molecules for their survival and
growth even if their own fatty acid
biosynthesis pathways are blocked [4].
Thus, to improve target selection for
medical structural genomics, it will be
important to collaborate with chemical
biology groups to undertake screening
campaigns to identify compounds that
cause the death of a pathogen under the
appropriate assay conditions [5].
If the target protein of a drug is known,
medical structural genomics offers a rapid
and efficient way to obtain ligand-bound
structures by using high-throughput X-ray
crystallography and/or NMR. Converse-
ly, when the target of a cell-active
compound is unknown, medical structural
genomics efforts provide purified protein
for many potential drug targets that can be
screened for interaction with the active
compound by a number of biophysical
methods (such as thermal stability [6]).
The Medicinal Structural Genomics of
Protozoan Pathogens (MSGPP, http://
www.msgpp.org/) initiative has already
begun such an effort by screening thou-
sands of anti-malaria compounds against
67 potential Plasmodium falciparum targets
expressed in bacteria (WC Van Voorhis,
unpublished data). These approaches aim
to generate knowledge about the biological
effect of a small molecule on a target
protein. Follow-up experiments are then
needed to test the activity of this com-
pound in live organisms in order to
validate the target; this valuable ‘‘chemical
validation’’ makes the target much more
likely to be drugable, and thus worthy of
more intensive effort. The future will likely
see more medical structural genomics
centers working with chemical biology
groups that have collections of ‘‘pheno-
type-defined’’ compounds (i.e., those with
known anti-pathogen activity). The result
will be synergistic target validation and
hit-to-lead development using structure-
based drug design.
Fragment-Based Drug
Discovery
Fragment-based drug discovery has rapid-
ly gained interest within the pharmaceutical
industry (reviewed in [7] with roots of 128-
compound cocktails in [8]), as an alternative
to expensive and sometimes inefficient high-
throughput screening methods for hit identi-
fication and optimization [9]. The general
concept of fragment-based drug discovery
involves screening libraries of ‘‘rule-of-three’’
compounds [10] against target macromole-
cules by using a variety of methods including
X-ray crystallography, NMR, surface plas-
mon resonance, differential thermal denatur-
ation, fluorescence polarization, and other
techniques [7,11–14]. The rule of three
consists of molecular weight ,300 daltons,
#3 rotatable bonds, #3h y d r o g e nb o n d
donors/acceptors, and Clog P (calculated log
of octanol/water partition coefficient) ,3.
These compounds generally include frag-
ments or ‘‘building blocks’’ of available drugs,
on the assumption that these fragments are
more likely to be ‘‘drug-like.’’ Fragment-
based drug discovery has been used by
commercial and academic groups, including
our own, and has led to a number of leads for
further drug development [15]. At deCODE
biostructures, a partner in the Seattle Struc-
tural Genomics Center for Infectious Disease
(SSGCID, http://www.ssgcid.org/) consor-
tium, the approach to assembling a fragment
library has been somewhat different. The
Fragments of Life (FOL) library (Figure 1) is a
collection of approximately 1,400 structurally
diverse small molecules found in the cellular
environment, metabolites, natural products,
and their derivatives or isosteres (molecules of
Table 1. Examples of how target protein structure can assist drug discovery and development.
Source Target Protein Approach Reference(s)
HIV gp41 Structure led to strategies that target viral entry. [43–45]
HIV Protease Protease–inhibitor complexes allowed lead optimization. [46–52]
HIV Reverse transcriptase Non-nucleoside inhibitor complexes led to drug design that targets
pockets outside the enzyme’s active site.
[53–55]
Influenza virus Neuraminidase Complex with a transition state analog led to inhalable and orally active
neuraminidase inhibitors.
[56–59]
Rhinovirus Coat protein Small fatty acid molecules bound in hydrophobic pocket led to new
strategies of antiviral drug design.
[60]
Vibrio Cholera toxin Five receptor-binding sites provided inspiration for design of novel
multivalent inhibitors.
[61]
Bacteria Peptide deformylase Protein–inhibitor complexes led to macrocyclic compounds with
improved potency, selectivity and metabolic stability.
[62]
Trypanosoma GAPDH Novel adenosine analogs showed enhanced selectivity towards the
parasite target versus human protein.
[63,64]
Human Cyclophilin and calcineurin A ternary complex with cyclosporine A led to insights into its
immunosuppressive activity.
[65]
Human Renin The ligand-bound structure allowed design and improvement of orally
active non-peptide inhibitors to regulate blood pressure.
[66]
Human Coagulation factor Xa Structure-based design led to improved pharmacological anticoagulant
properties in a primate model.
[67]
Human Adenosine deaminase Optimization of a non-nucleoside inhibitor led to an orally active
anti-inflammatory compound in a rat model.
[68]
Human Kinases Structures of kinases provided a basis to improve and design new
therapeutics for various human diseases including cancer.
[69]
doi:10.1371/journal.pcbi.1000530.t001
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types of atoms). Also included in the FOL
library are a series of biaryl small molecules
(which contain two tethered five- or six-
membered ring structures) that mimicprotein
secondary structure elements (e.g., a-helical
turns). Thus, this fragment set is useful for
targeting both the active sites of enzymes and
more complex protein surfaces including
allosteric small molecule binding sites and
protein–protein interfaces [16].
Targeting Oligomeric Enzymes
Protein–protein interaction and assem-
blies, ranging from simple dimers to
extremely complex arrangements as seen
in the ribosome or the nuclear pore
complex, form the basis of most biological
processes, and there are usually numerous
points of contact between the macromol-
ecules involved. Yet the protein–protein
interfaces formed by oligomerization are
not necessarily accompanied by a large
gain in free energy, and small molecules
have been shown to prevent critical
protein–protein interactions [17]. These
Table 2. Structural genomics projects worldwide submitting to the Protein Data Bank.
Name URL Target Focus
Berkeley Structural Genomics Center (BSGC) http://www.strgen.org/ Near complete coverage of Mycoplasma genome
Center for Eukaryotic Structural Genomics (CESG) http://www.uwstructuralgenomics.org/ PSI Center—Eukaryotic bottlenecks, specifically solubility
Center for Structural Genomics of Infectious Disease
(CSGID)
http://csgid.org/csgid/ Medically relevant infectious disease targets
Center for Structure of Membrane Proteins (CSMP) http://csmp.ucsf.edu/index.htm PSI Center—Bacterial and human membrane proteins
Integrated Center for Structure and Function
Innovation (ISFI)
htp://techcenter.mbi.ucla.edu/ PSI Center—Protein solubility and crystallization
improvement
Israel Structural Proteomics Center http://www.weizmann.ac.il/ISPC/ Member of Structural Proteomics in Europe (see
below)
Joint Center for Structural Genomics (JCSG) http://www.jcsg.org/ PSI Center—High-throughput pipeline development
and operation
Marseilles Structural Genomics Program http://www.afmb.univ-mrs.fr/rubrique93.html Human health
Medical Structural Genomics of Pathogenic
Protozoa (MSGPP)
http://www.msgpp.org/ Structural and functional genomics of ten species of
pathogenic protozoa
Montreal-Kingston Bacterial Structural Genomics
Initiative (BSGI)
http://euler.bri.nrc.ca/brimsg/bsgi.html ORFs from pathogenic and nonpathogenic bacterial
strains
Mycobacterium Tuberculosis Structural Genomics
Consortium (TBsgc)
http://www.doe-mbi.ucla.edu/TB/ Mycobacterium tuberculosis—To understand
pathogenesis and for structure-based drug design
Mycobacterium Tuberculosis Structural Proteomics
Project (X-MTB)
http://webclu.bio.wzw.tum.de/binfo/proj/mtb/ 35 Mycobacterium tuberculosis targets to identify five
for drug development
New York SGX Research Center for Structural
Genomics (NYSGXRC)
http://www.nysgrc.org/nysgrc/ PSI Center—High-throughput pipeline development
and operation
Ontario Center for Structural Proteomics (OCSP) http://www.uhnres.utoronto.ca/centres/proteomics/ Enzymatic activity characterization
Oxford Protein Production Facility http://www.oppf.ox.ac.uk/OPPF/ Human and pathogen targets of biomedical
relevance
RIKEN Structural Genomics/Proteomics Initiative http://www.rsgi.riken.jp/rsgi_e/ Protein functional networks
Seattle Structural Genomics Center for Infectious
Disease (SSGCID)
http://www.ssgcid.org/ Medically relevant infectious disease targets
Southeast Collaboratory for Structural Genomics http://www.secsg.org/ High-throughput eukaryotic genome-scan methods
development
Structural Genomics of Pathogenic Protozoa http://www.sgpp.org/ PSI Center - Three-dimensional structures of proteins
from four major pathogenic protozoa
Structural Proteomics in Europe (SPINE) http://www.spineurope.org/ Structures of medically relevant proteins and protein
complexes
Structural Proteomics in Europe 2-Complexes
(SPINE2 - Complexes)
http://www.spine2.eu/SPINE2/ Structures of protein complexes from medically
relevant signaling pathways
Structural Genomics Consortium http://www.thesgc.org/ Medically relevant human and pathogen proteins
Structure 2 Function Project http://s2f.umbi.umd.edu/ Poorly characterized and hypothetical protein targets
The Accelerated Technologies Center for Gene
to 3D Structure
http://atcg3d.org/default.aspx PSI Center—Technologies development of X-ray
source, synthetic gene design, and microfluidic
crystallization
The Midwest Center for Structural Genomics
(MCSG)
http://www.mcsg.anl.gov/ PSI Center—High-throughput methods development
and operation
The Northeast Structural Genomics Consortium
(NESG)
http://www.nesg.org/ PSI Center—Protein domains, network families,
biomedical relevance
Note: Some centers with fewer than ten released structures in the PDB (www.rcsb.org/pdb/) are not shown.
PSI, Protein Structure Initiative.
doi:10.1371/journal.pcbi.1000530.t002
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of a structure-based approach aimed at
developing novel small-molecule antibiot-
ics that modulate protein activity by
binding to an interface between subunits
within multi-protein complexes [18]. The
bacterial enzyme inorganic pyrophospha-
tase may serve as an example for this
approach, since it exists in a hexameric
state that requires conformational flexibil-
ity for its essential role in converting
inorganic pyrophosphate into phosphate
[19–21]. Moreover, whereas all bacterial
inorganic pyrophosphatases function as a
homohexamer, the eukaryotic cytosolic
and mitochondrial inorganic pyrophos-
phatases function as homodimers [21].
Hence eukaryotic inorganic pyrophospha-
tases have different oligomeric interfaces
than those of bacterial enzymes. This
suggests that it may be possible to inhibit
the bacterial inorganic pyrophosphatase
safely by targeting its oligomeric state
rather than its highly conserved active
site. A similar approach has recently been
used to identify species-specific modulators
of porphobilinogen synthase (PBGS) ac-
tivity [22]. SSGCID has solved the high-
resolution X-ray crystal structure of inor-
ganic pyrophosphatase from the patho-
genic bacterium Burkholderia pseudomallei,
and a subsequent FOL screen of this target
identified several fragments that specifical-
ly bind at multiple oligomerization pockets
in a molecular interface between the two
trimers of the homohexamer (Figure 2).
While these fragments remain to be
validated in terms of their species-specific
inhibition of inorganic pyrophosphatase
activity, they represent potential starting
points for the development of novel
antibiotics.
Industry-Generated Structures
and the Protein Data Bank
As we have seen above, protein struc-
ture information is the bread and butter of
structure-based drug discovery. Structural
genomics projects (Table 2) have substan-
tially increased the number of protein
structures solved and have made this
information freely and openly available
(i.e., at no cost and without restriction by
copyright or other constraints) by depos-
iting it in the Protein Data Bank (PDB)
[23]. Most publishers have policies that
require authors to deposit structural data
in the PDB at the time of publication, so
structures determined by academic re-
searchers worldwide are, for the most
part, well disseminated. By contrast, the
pharmaceutical industry is sitting on a
mountain of structural data for protein–
ligand complexes from globally important
pathogens, which is not available to the
wider scientific community. The secrecy
engendered by the current economic
incentives driving drug discovery in the
commercial sector has led to a substantial
waste of precious resources through dupli-
cation of effort and inability to learn from
others’ successes and failures. The situa-
tion is unlikely to change without a
concerted effort to find ways to overcome
the financial and intellectual property
barriers that prevent dissemination of this
information. A recent publication suggest-
ed that open access industry–academia
partnerships may provide one possible
model [24]. We propose that the United
States National Institutes of Health, along
with other national and international
research-funding agencies, issue calls for
proposals that will fund the transfer of the
highly valuable structural information
from corporate databases into the PDB.
Such an effort would obviously require
discussion with industrial parties to nego-
tiate mutually acceptable policies and
mechanisms for the deposition of these
structures in the public databases. These
might include relaxation of release stan-
dards for industrial entities, such that
structural information could be safely
deposited in PDB at the time of structure
Figure 1. Conceptual organization of the deCODE biostructures Fragments of Life library. The current ,1,400-compound library contains
chemically tractable natural small molecule metabolites (FOL-Nat), metabolite-like compounds and their bioisosteres (FOL-NatD), and biaryl mimetics
of protein architecture (FOL-Biaryl). The FOL-Nat members include any natural molecule of molecular weight ,350 daltons that exists as a substrate,
natural product, or allosteric regulator of any metabolic pathway in any cell type, such as the biosynthetic pathways for the neurotransmitter
serotonin (1) and the plant hormone auxin (2). The FOL-Nat members also include secondary metabolites such as bestatin (3), a secondary
metabolite of Streptomyces olivoreticuli [38]. FOL-NatD fragments are defined as heteroatom-containing derivatives, isosteres, or analogs of any FOL-
Nat molecule. For example, fragments 4–7 contain the indole scaffold, which is known to be a privileged building block for drug molecules [39]. To
emulate protein architecture, the FOL-Biaryl fragments were selected from a variety of biaryl compounds that are potential mimics of protein a, b,o r
c turns [40–42]. These include a compound (8) whose structure in an energy-minimized state can be seen to mimic the architecture on an a-turn of a
protein structure (here, residues Ser65-Ile66-Leu67-Lys68 of PDB ID:1RTP) and, similarly, a compound (9) whose structure mimics the b-turn of a
protein structure (residues Ala20-Ala21-Asp22-Ser23).
doi:10.1371/journal.pcbi.1000530.g001
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date more appropriate for protection of
intellectual property.
Challenges for the Future
We are currently witnessing an explo-
sion in technological and computational
advances in structural genomics, with
protein structures of hundreds or thou-
sands of medically relevant targets from
infectious disease organisms likely to be
available over the next few years. This new
information provides both academic and
for-profit scientists with an unprecedented
opportunity to accelerate the development
of new and improved chemotherapeutic
agents against these pathogens. One major
challenge will be the adaptation of existing
fragment-based drug design methods to
match the scale of the structural genomics
era. New high-throughput methods need
to be developed for fragment-screening to
enhance the success rate for protein–
ligand structure determination.
Major attention is also needed to the
development of fully automated, very high
throughput crystal growth screening meth-
ods to elucidate the binding of well-
selected compounds to medically relevant
targets. These screens need to cover many
(up to 100) protein variants [25,26],
1,000–10,000 different small molecule
compounds, and approximately 1,000
different crystal growth conditions [27],
resulting in 10
8 to 10
9 conditions to be
tested for a single drug target. Obviously,
this will require development of even
smaller volume assays than those currently
in use [28–31]—down to the low pico-
liters—and automated detection of crystals
in the millions of crystallization chambers
[32–34]. Further development of automat-
ed capillary crystallization methods [35]
might provide another way to achieve the
very high throughput crystal screening
required for reaching the full power of
medical structural genomics in the future.
Cryoprotection of the crystals is a specific
hurdle, although it might be possible to
routinely collect and merge partial datasets
from multiple crystals under non-cryo
conditions. Alternatively, the use of micro-
meshes [36,37] and further miniaturiza-
tion of trays and other crystal screening
tools may allow cryoprotection of many
crystals simultaneously.
In addition, existing databases will need
to be modified to allow easy dissemination
of the results from these fragment screens,
and a serious effort should be made to
persuade small and big pharma to release
coordinates of drug targets from globally
important infectious disease organisms. It
will also be critical (but challenging) for
structural biologists to collaborate with
medicinal chemists and molecular biolo-
gists to turn these fragment from promis-
ing leads to effective drugs. Together,
these steps should begin to release a flood
of structures that provide a tremendous
resource for improving health in rich and
poor countries alike.
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Figure 2. B. pseudomallei inorganic pyrophosphatase with bound ligand at an oligomeric interface. Homo-hexameric bacterial inorganic
pyrophosphatase is a dimer of trimers (blue and green). The illustration shows the hexamer structure in a complex with three ligand fragment
molecules (red spheres and stick structures represent fragment FOL 110), each of which is located at one of three ‘‘dimer of trimer’’ interfaces (1.5
ligands per monomer) (PDBID:3EJ0). The location of one pyrophosphate substrate (cyan spheres) at the active site of one of the monomers is
indicated here based on the superimposed structure of the hexamer with pyrophosphate bound in the active site (PDBID:3EIY). The binding sites of
the ligands (red) are clearly seen in a pocket formed by the homo-oligomeric assemblage, which is distant from the active site where pyrophosphate
(cyan) binds.
doi:10.1371/journal.pcbi.1000530.g002
PLoS Computational Biology | www.ploscompbiol.org 5 October 2009 | Volume 5 | Issue 10 | e1000530References
1. Payne DJ, Gwynn MN, Holmes DJ,
Pompliano DL (2007) Drugs for bad bugs:
Confronting the challenges of antibacterial dis-
covery. Nat Rev Drug Discov 6: 29–40.
2. Haquin S, Oeuillet E, Pajon A, Harris M,
Jones AT, et al. (2008) Data management in
structural genomics: An overview. Methods Mol
Biol 426: 49–79.
3. Wright HT, Reynolds KA (2007) Antibacterial
targets in fatty acid biosynthesis. Curr Opin
Microbiol 10: 447–453.
4. Brinster S, Lamberet G, Staels B, Trieu-Cuot P,
Gruss A, et al. (2009) Type II fatty acid synthesis
is not a suitable antibiotic target for gram-positive
pathogens. Nature 458: 83–86.
5. Hoon S, Smith AM, Wallace IM, Suresh S,
Miranda M, et al. (2008) An integrated platform
of genomic assays reveals small-molecule bioac-
tivities. Nat Chem Biol 4: 498–506.
6. Ericsson UB, Hallberg BM, Detitta GT,
Dekker N, Nordlund P (2006) Thermofluor-based
high-throughput stability optimization of proteins
for structural studies. Anal Biochem 357:
289–298.
7. Congreve M, Chessari G, Tisi D, Woodhead AJ
(2008) Recent developments in fragment-based
drug discovery. J Med Chem 51: 3661–3689.
8. Verlinde CLMJ, Kim H, Bernstein BE,
Mande SC, Hol WG (1997) Antitrypanosomiasis
drug development based on structures of glyco-
lytic enzymes. In: Veerapandian P, ed. Structure-
based drug design. New York: Marcel Dekker. pp
365–394.
9. Rees DC, Congreve M, Murray CW, Carr R
(2004) Fragment-based lead discovery. Nat Rev
Drug Discov 3: 660–672.
10. Congreve M, Carr R, Murray C, Jhoti H (2003)
A ‘‘rule of three’’ for fragment-based lead
discovery? Drug Discov Today 8: 876–877.
11. Nienaber VL, Greer J (2000) Discovering novel
ligands for macromolecules using X-ray crystal-
lographic screening. Nature Biotechnol 18:
1105–1108.
12. Neumann T, Junker HD, Schmidt K, Sekul R
(2007) SPR-based fragment screening: Advantag-
es and applications. Curr Top Med Chem 7:
1630–1642.
13. Jhoti H, Cleasby A, Verdonk M, Williams G
(2007) Fragment-based screening using X-ray
crystallography and NMR spectroscopy. Curr
Opin Chem Biol 11: 485–493.
14. Erlanson DA (2006) Fragment-based lead discov-
ery: A chemical update. Curr Opin Biotechnol
17: 643–652.
1 5 .B o s c hJ ,R o b i e nM A ,M e h l i nC ,B o n iE ,
Riechers A, et al. (2006) Using fragment cocktail
crystallography to assist inhibitor design of
Trypanosoma brucei nucleoside 2-deoxyribosyltrans-
ferase. J Med Chem 49: 5939–5946.
16. Davies DR, Mamat B, Magnusson OT,
Christensen J, Haraldsson MH, et al. (2009)
Discovery of leukotriene A4 hydrolase inhibitors
using metabolomics biased fragment crystallog-
raphy. J Med Chem 52: 4694–4715.
17. Liuzzi M, Deziel R, Moss N, Beaulieu P,
Bonneau AM, et al. (1994) A potent peptidomi-
metic inhibitor of HSV ribonucleotide reductase
with antiviral activity in vivo. Nature 372:
695–698.
18. Wells JA, McClendon CL (2007) Reaching for
high-hanging fruit in drug discovery at protein-
protein interfaces. Nature 450: 1001–1009.
19. Kankare J, Salminen T, Lahti R, Cooperman BS,
Baykov AA, et al. (1996) Structure of Escherichia
coli inorganic pyrophosphatase at 2.2 A ˚ resolu-
tion. Acta Crystallogr D Biol Crystallogr 52:
551–563.
20. Oksanen E, Ahonen AK, Tuominen H,
Tuominen V, Lahti R, et al. (2007) A complete
structural description of the catalytic cycle of
yeast pyrophosphatase. Biochemistry 46:
1228–1239.
21. Sivula T, Salminen A, Parfenyev AN,
Pohjanjoki P, Goldman A, et al. (1999) Evolu-
tionary aspects of inorganic pyrophosphatase.
FEBS Lett 454: 75–80.
22. Lawrence SH, Ramirez UD, Tang L, Fazliyez F,
Kundrat L, et al. (2008) Shape shifting leads to
small-molecule allosteric drug discovery. Chem
Biol 15: 586–596.
23. Berman H, Henrick K, Nakamura H, Markley JL
(2007) The worldwide Protein Data Bank
(wwPDB): Ensuring a single, uniform archive of
PDB data. Nucleic Acids Res 35: D301–303.
24. Edwards AM, Bountra C, Kerr DJ, Willson TM
(2009) Open access chemical and clinical probes
to support drug discovery. Nat Chem Biol 5:
436–440.
25. Choi KH, Groarke JM, Young DC,
Rossmann MG, Pevear DC, et al. (2004) Design,
expression, and purification of a Flaviviridae
polymerase using a high-throughput approach to
facilitate crystal structure determination. Protein
Sci 13: 2685–2692.
26. Graslund S, Sagemark J, Berglund H,
Dahlgren LG, Flores A, et al. (2008) The use of
systematic N- and C-terminal deletions to
promote production and structural studies of
recombinant proteins. Protein Expr Purif 58:
210–221.
27. Luft JR, Collins RJ, Fehrman NA, Lauricella AM,
Veatch CK, et al. (2003) A deliberate approach to
screening for initial crystallization conditions of
biological macromolecules. J Struct Biol 142:
170–179.
28. Santarsiero BDYD, Lee CC, Spraggon G, Gu J,
ScheibeD,UberEC,CornellEW,NordmeyerRA,
K o l b eW F ,J i nJ ,J o n e sA L ,J a k l e v i cJ M ,
Schultz PG, Stevens RC (2002) An approach to
rapid protein crystallization using nanodroplets.
J Appl Crystallogr 35: 278–281.
29. Hansen CL, Skordalakes E, Berger JM, Quake SR
(2002) A robust and scalable microfluidic meter-
ing method that allows protein crystal growth by
free interface diffusion. Proc Natl Acad Sci U S A
99: 16531–16536.
30. Zheng B, Roach LS, Ismagilov RF (2003)
Screening of protein crystallization conditions
on a microfluidic chip using nanoliter-size
droplets. J Am Chem Soc 125: 11170–11171.
31. Gerdts CJ, Elliott M, Lovell S, Mixon MB,
Napuli AJ, et al. (2008) The plug-based nanovo-
lume Microcapillary Protein Crystallization Sys-
tem (MPCS). Acta Crystallogr D Biol Crystallogr
64: 1116–1122.
32. Wilson J (2002) Towards the automated evalua-
tionofcrystallizationtrials.ActaCrystallogrDBiol
Crystallogr 58: 1907–1914.
33. Pan S, Shavit G, Penas-Centeno M, Xu DH,
Shapiro L, et al. (2006) Automated classification
of protein crystallization images using support
vector machines with scale-invariant texture and
Gabor features. Acta Crystallogr D Biol Crystal-
logr 62: 271–279.
34. Liu R, Freund Y, Spraggon G (2008) Image-
based crystal detection: A machine-learning
approach. Acta Crystallogr D Biol Crystallogr
64: 1187–1195.
35. Fan E, Baker D, Fields S, Gelb MH, Buckner FS,
et al. (2008) Structural genomics of pathogenic
protozoa: An overview. Methods Mol Biol 426:
497–513.
36. WagnerA,DiezJ,Schulze-BrieseC,SchluckebierG
(2009) Crystal structure of ultralente—A microcrys-
talline insulin suspension. Proteins 74: 1018–1027.
37. Thorne RESZ, Kmetko J, O’Niell J, Gillilan R
(2003) Microfabricated mounts for high-through-
put macromolecular cryocrystallography.
J Applied Crystallography 36: 1455–1460.
38. Schorlemmer HU, Bosslet K, Dickneite G,
Luben G, Sedlacek HH (1984) Studies on the
mechanisms of action of the immunomodulator
Bestatin in various screening test systems. Behring
Inst Mitt: 157–173.
39. Costantino L, Barlocco D (2006) Privileged
structures as leads in medicinal chemistry. Curr
Med Chem 13: 65–85.
40. Biros SM, Moisan L, Mann E, Carella A, Zhai D,
et al. (2007) Heterocyclic alpha-helix mimetics for
targeting protein-protein interactions. Bioorg
Med Chem Lett 17: 4641–4645.
41. Robinson JA (2008) Beta-hairpin peptidomi-
metics: design, structures and biological activities.
Acc Chem Res 41: 1278–1288.
42. Saraogi I, Hamilton AD (2008) alpha-Helix
mimetics as inhibitors of protein-protein interac-
tions. Biochem Soc Trans 36: 1414–1417.
43. Root MJ, Steger HK (2004) HIV-1 gp41 as a
target for viral entry inhibition. Curr Pharm Des
10: 1805–1825.
44. Weissenhorn W, Dessen A, Harrison SC,
Skehel JJ, Wiley DC (1997) Atomic structure of
the ectodomain from HIV-1 gp41. Nature 387:
426–430.
45. Ferrer M, Kapoor TM, Strassmaier T,
Weissenhorn W, Skehel JJ, et al. (1999) Selection
of gp41-mediated HIV-1 cell entry inhibitors
from biased combinatorial libraries of non-
natural binding elements. Nat Struct Biol 6:
953–960.
46. Lapatto R, Blundell T, Hemmings A,
Overington J, Wilderspin A, et al. (1989) X-ray
analysis of HIV-1 proteinase at 2.7 A ˚ resolution
confirms structural homology among retroviral
enzymes. Nature 342: 299–302.
47. Miller M, Schneider J, Sathyanarayana BK,
Toth MV, Marshall GR, et al. (1989) Structure
of complex of synthetic HIV-1 protease with a
substrate-based inhibitor at 2.3 A ˚ resolution.
Science 246: 1149–1152.
48. Navia MA, Fitzgerald PM, McKeever BM,
Leu CT, Heimbach JC, et al. (1989) Three-
dimensional structure of aspartyl protease from
human immunodeficiency virus HIV-1. Nature
337: 615–620.
4 9 .W l o d a w e rA ,M i l l e rM ,J a s k o l s k iM ,
Sathyanarayana BK, Baldwin E, et al. (1989)
Conserved folding in retroviral proteases: Crystal
structure of a synthetic HIV-1 protease. Science
245: 616–621.
50. Wlodawer A, Vondrasek J (1998) Inhibitors of
HIV-1 protease: A major success of structure-
assisted drug design. Annu Rev Biophys Biomol
Struct 27: 249–284.
51. Abdel-Rahman HM, Al-karamany GS, El-
Koussi NA, Youssef AF, Kiso Y (2002) HIV
protease inhibitors: Peptidomimetic drugs and
future perspectives. Curr Med Chem 9:
1905–1922.
52. Chrusciel RA, Strohbach JW (2004) Non-peptidic
HIV protease inhibitors. Curr Top Med Chem 4:
1097–1114.
53. Das K, Lewi PJ, Hughes SH, Arnold E (2005)
Crystallography and the design of anti-AIDS
drugs: Conformational flexibility and positional
adaptability are important in the design of non-
nucleoside HIV-1 reverse transcriptase inhibitors.
Prog Biophys Mol Biol 88: 209–231.
54. Kohlstaedt LA, Wang J, Friedman JM, Rice PA,
Steitz TA (1992) Crystal structure at 3.5 A ˚
resolution of HIV-1 reverse transcriptase com-
plexed with an inhibitor. Science 256: 1783–1790.
55. Smerdon SJ, Jager J, Wang J, Kohlstaedt LA,
Chirino AJ, et al. (1994) Structure of the binding
site for nonnucleoside inhibitors of the reverse
transcriptase of human immunodeficiency virus
type 1. Proc Natl Acad Sci U S A 91: 3911–3915.
56. Babu YS, Chand P, Bantia S, Kotian P,
Dehghani A, et al. (2000) BCX-1812 (RWJ-
270201): Discovery of a novel, highly potent,
orally active, and selective influenza neuramini-
PLoS Computational Biology | www.ploscompbiol.org 6 October 2009 | Volume 5 | Issue 10 | e1000530dase inhibitor through structure-based drug
design. J Med Chem 43: 3482–3486.
5 7 .B o s s a r t - W h i t a k e rP ,C a r s o nM ,B a b uY S ,
Smith CD, Laver WG, et al. (1993) Three-
dimensional structure of influenza A N9 neur-
aminidase and its complex with the inhibitor 2-
deoxy 2,3-dehydro-N-acetyl neuraminic acid.
J Mol Biol 232: 1069–1083.
58. Kim CU, Lew W, Williams MA, Liu H, Zhang L,
et al. (1997) Influenza neuraminidase inhibitors
possessing a novel hydrophobic interaction in the
enzyme active site: Design, synthesis, and struc-
tural analysis of carbocyclic sialic acid analogues
with potent anti-influenza activity. J Am Chem
Soc 119: 681–690.
59. von Itzstein M, Wu WY, Kok GB, Pegg MS,
Dyason JC, et al. (1993) Rational design of potent
sialidase-based inhibitors of influenza virus repli-
cation. Nature 363: 418–423.
60. Hadfield AT, Lee W, Zhao R, Oliveira MA,
Minor I, et al. (1997) The refined structure of
human rhinovirus 16 at 2.15 A ˚ resolution:
Implications for the viral life cycle. Structure 5:
427–441.
61. Merritt EA, Zhang Z, Pickens JC, Ahn M,
Hol WG, et al. (2002) Characterization and
crystal structure of a high-affinity pentavalent
receptor-binding inhibitor for cholera toxin and
E. coli heat-labile enterotoxin. J Am Chem Soc
124: 8818–8824.
62. Hu X, Nguyen KT, Jiang VC, Lofland D,
Moser HE, et al. (2004) Macrocyclic inhibitors
for peptide deformylase: A structure-activity
relationship study of the ring size. J Med Chem
47: 4941–4949.
63. Aronov AM, Verlinde CL, Hol WG, Gelb MH
(1998) Selective tight binding inhibitors of try-
panosomal glyceraldehyde-3-phosphate dehydro-
genase via structure-based drug design. J Med
Chem 41: 4790–4799.
64. Bressi JC, Choe J, Hough MT, Buckner FS, Van
Voorhis WC, et al. (2000) Adenosine analogues as
inhibitors of Trypanosoma brucei phosphoglycerate
kinase: Elucidation of a novel binding mode for a
2-amino-N(6)-substituted adenosine. J Med Chem
43: 4135–4150.
65. Jin L, Harrison SC (2002) Crystal structure of
human calcineurin complexed with cyclosporin A
and human cyclophilin. Proc Natl Acad Sci U S A
99: 13522–13526.
66. Rahuel J, Rasetti V, Maibaum J, Rueger H,
Goschke R, et al. (2000) Structure-based drug
design: The discovery of novel nonpeptide orally
active inhibitors of human renin. Chem Biol 7:
493–504.
67. Lam PY, Clark CG, Li R, Pinto DJ, Orwat MJ,
et al. (2003) Structure-based design of novel
guanidine/benzamidine mimics: Potent and oral-
ly bioavailable factor Xa inhibitors as novel
anticoagulants. J Med Chem 46: 4405–4418.
68. Terasaka T, Kinoshita T, Kuno M, Seki N,
Tanaka K, et al. (2004) Structure-based design,
synthesis, and structure-activity relationship stud-
ies of novel non-nucleoside adenosine deaminase
inhibitors. J Med Chem 47: 3730–3743.
69. Noble ME, Endicott JA, Johnson LN (2004)
Protein kinase inhibitors: Insights into drug design
from structure. Science 303: 1800–1805.
PLoS Computational Biology | www.ploscompbiol.org 7 October 2009 | Volume 5 | Issue 10 | e1000530